Therapy of localized esophageal cancer: It is time to reengineer our investigative strategies

Onkologie

Volumn 31, Issue 7, 2008, Pages 360-361

  Ajani, Jaffer ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAMPTOTHECIN; CISPLATIN; DOCETAXEL; FLUOROPYRIMIDINE; FLUOROURACIL; PACLITAXEL; PLATINUM; TAXANE DERIVATIVE;

CANCER CHEMOTHERAPY; CANCER LOCALIZATION; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER SURVIVAL; EDITORIAL; ESOPHAGUS CANCER; HUMAN; MORBIDITY;

ANTINEOPLASTIC AGENTS; BIOMEDICAL RESEARCH; COMBINED MODALITY THERAPY; ESOPHAGEAL NEOPLASMS; HUMANS;

EID: 47049083743     PISSN: 0378584X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000137836     Document Type: Editorial

References (23)

1. Pohl H, Welch HG: The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. J Natl Cancer Inst 2005;97:142-146.
2. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ: Cancer statistics, 2008. CA Cancer J Clin 2008;58:71-96.
3. Cooper JS, Guo MD, Herskovic A, Macdonald JS, Martenson JA, Jr., Al-Sarraf M, Byhardt R, Russell AH, Beitler JJ, Spencer S, Asbell SO, Graham MV, Leichman LL: Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (rtog 85-01). Radiation therapy oncology group. JAMA 1999;281:1623-1627.
4. Tepper J, Krasna MJ, Niedzwiecki D, Hollis D, Reed CE, Goldberg R, Kiel K, Willett C, Sugarbaker D, Mayer R: Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: Calgb 9781. J Clin Oncol 2008;26:1086-1092.
5. Bosset JF, Gignoux M, Triboulet JP, Tiret E, Mantion G, Elias D, Lozach P, Ollier JC, Pavy JJ, Mercier M, Sahmoud T: Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus. N Engl J Med 1997;337:161-167.
6. Walsh TN, Noonan N, Hollywood D, Kelly A, Keeling N, Hennessy TP: A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med 1996;335:462-467.
7. Urba SG, Orringer MB, Turrisi A, Iannettoni M, Forastiere A, Strawderman M: Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. J Clin Oncol 2001;19:305-313.
8. Suntharalingam M, Moughan J, Coia LR, Krasna MJ, Kachnic L, Haller DG, Willet CG, John MJ, Minsky BD, Owen JB: Outcome results of the 1996-1999 patterns of care survey of the national practice for patients receiving radiation therapy for carcinoma of the esophagus. J Clin Oncol 2005;23:2325-2331.
9. Javeri H, Arora R, Correa AM, Hofstetter WL, Lee JH, Liao Z, McAleer MF, Maru D, Bhutani MS, Swisher SG, Izzo JG, Ajani JA: Influence of induction chemotherapy and class of cytotoxics on pathologic response and survival after preoperative chemoradiation in patients with carcinoma of the esophagus. Cancer 2008; in press.
10. Mellinghoff IK, Wang MY, Vivanco I, Haas-Kogan DA, Zhu S, Dia EQ, Lu KV, Yoshimoto K, Huang JH, Chute DJ, Riggs BL, Horvath S, Liau LM, Cavenee WK, Rao PN, Beroukhim R, Peck TC, Lee JC, Sellers WR, Stokoe D, Prados M, Cloughesy TF, Sawyers CL, Mischel PS: Molecular determinants of the response of glioblastomas to egfr kinase inhibitors. N Engl J Med 2005;353:2012-2024.
11. Sharma SV, Bell DW, Settleman J, Haber DA: Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 2007;7:169-181.
12. Ajani JA, Winter K A, Komaki R, Kelsen D P, Minsky B D, Liao Z, Bradley J, Fromm M, Hornback D, Willett C G: A phase II randomized trial of two non-operative approaches of induction chemotherapy followed by chemoradiation in patients with localized carcinoma of the esophagus. The radiation therapy oncology group 0113 study. J Clin Oncol 2008; in press.
13. Kelsen DP, Ginsberg R, Pajak TF, Sheahan DG, Gunderson L, Mortimer J, Estes N, Haller DG, Ajani J, Kocha W, Minsky BD, Roth JA: Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. N Engl J Med 1998;339:1979-1984.
14. Sawyers CL: The cancer biomarker problem. Nature 2008;452:548-552.
15. Chin L, Gray JW: Translating insights from the cancer genome into clinical practice. Nature 2008;452:553-563.
16. Bild AH, Yao G, Chang JT, Wang Q, Potti A, Chasse D, Joshi MB, Harpole D, Lancaster JM, Berchuck A, Olson JA, Jr., Marks JR, Dressman HK, West M, Nevins JR: Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 2006;439:353-357.
17. Ott K, Herrmann K, Lordick F, Wieder H, Weber WA, Becker K, Buck AK, Dobritz M, Fink U, Ulm K, Schuster T, Schwaiger M, Siewert JR, Krause BJ: Early metabolic response evaluation by fluorine-18 fluorodeoxyglucose positron emission tomography allows in vivo testing of chemosensitivity in gastric cancer: Long-term results of a prospective study. Clin Cancer Res 2008;14:2012-2018.
18. Lordick F, Ott K, Krause BJ, Weber WA, Becker K, Stein HJ, Lorenzen S, Schuster T, Wieder H, Herrmann K, Bredenkamp R, Hofler H, Fink U, Peschel C, Schwaiger M, Siewert JR: PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: The municon phase II trial. Lancet Oncol 2007;8:797-805.
19. Weissleder R, Pittet MJ: Imaging in the era of molecular oncology. Nature 2008;452:580-589.
20. Apisarnthanarax S, Alauddin MM, Mourtada F, Ariga H, Raju U, Mawlawi O, Han D, Bornmann WG, Ajani JA, Milas L, Gelovani JG, Chao KS: Early detection of chemoradioresponse in esophageal carcinoma by 3′-deoxy-3′-3h- fluorothymidine using preclinical tumor models. Clin Cancer Res 2006;12:4590-4597.
21. Bader FG, Lordick F, Fink U, Becker K, Hofler H, Busch R, Siewert J R, Ott K: Paclitaxel in the neoadjuvant treatment for adenocarcinoma of the distal esophagus. A comparison of two phase II trials with long-term follow-up. Onkologie 2008;31:366-372.
22. Kelsey CR, Chino JP, Willett CG, Clough RW, Hurwitz HI, Morse MA, Bendell JC, D'Amico TA, Czito BG: Paclitaxel-based chemoradiotherapy in the treatment of patients with operable esophageal cancer. Int J Radiat Oncol Biol Phys 2007;69:770-776.
23. Van Cutsem E, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, Rodrigues A, Fodor M, Chao Y, Voznyi E, Risse ML, Ajani JA: Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: A report of the v325 study group. J Clin Oncol 2006;24:4991-4997.